Abstract 33P
Background
Inaccuracy in reporting methods and results in published literature is a major issue as it challenges not only the interpretation of conclusions but also the ability to accurately compare studies. The existing REMARK (REporting recommendations for tumour MARKer prognostic studies) guideline aims to improve the reporting of tumour biomarker prognostic studies. However, for generic translational cancer genomic studies no standard currently exists. We developed modified REMARK (m-REMARK) criteria to ensure transparency and standardized reporting of these kinds of studies.
Methods
Key elements to be addressed in the proposed checklist were identified by the proposing panel and ICGC ARGO members including experts in methodology, biostatistics, and preclinical, translational, and clinical cancer genomics. Several reporting guidelines produced for other types of medical research studies were reviewed. REMARK was used as a guide and was adapted to our purpose.
Results
A preliminary draft of m-REMARK was proposed in the context of a systematic review and meta-analysis recently published in the Journal of Clinical Oncology. Building on that work, the checklist is being re-discussed, revised, and improved by the ICGC ARGO network. For final approval, external revision by the REMARK community will be done.
Conclusions
After ICGC ARGO discussion, revision, and external approval, m-REMARK will be the new standard to be followed when designing and reporting translational cancer genomic studies. It will significantly impact on future cancer research and patient care.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.